PFNLive
- Stocks Briefly Drop, Recover, on Fake Bomb Tweet
- Bristol-Myers Hepatitis C Combo Therapy Blunts Disease
- Achillion Says Hepatitis C Drug Subdues Virus in 63% of Patients
- Orion Profit Falls on Generic Competition
- Wall Street Ends Higher, Led by Tech, Microsoft
- AstraZeneca Inks Cancer Deals with Bind Therapeutics, Horizon Discovery
- Bristol-Myers Rebounds on Hep C Front with New Merck Partnership
- Stocks Mixed as Major Companies Report Earnings
- Severe U.S. Flu Season Helps Reckitt Top Forecasts
- Sanofi Infant Vaccine gets EU Approval
- Stock Futures up with Full Earnings Calendar on Tap
- TiGenix Reports Positive Phase IIa Results in Arthritis
- Elan Board Unanimously Rejects Royalty Pharma Bid
- Takeda in More Trouble at Home over Recall of Mislabeled Vials
- Nasdaq Extends Gain, up 1 Percent on Tech Results
- Civitas Parkinson's Drug Improves Motor Fluctuations in Phase II Trial
- Astellas, GSK Vie to Make 'High Altitude' Anaemia Pill
- Intuitive Surgical Narrows 2013 Forecast, Shares Fall
- Wall Street Set to Rebound after Breaching Key Level
- Vertex Gains as Cystic Fibrosis Combo Eases Breathing
